North America Anti-Obesity Drugs Market Report and Forecast 2025-2034

North America Anti-Obesity Drugs Market Outlook

The North America anti-obesity drugs market size is expected to grow at a CAGR of 9.30% during the forecast period of 2024-2032, driven by the rising prevalence of obesity and the growing demand for effective anti-obesity drugs with fewer side effects in the region. 

Key Takeaways

• In the United States, 41.9% of adults are estimated to be obese. The rising prevalence of obesity directly impacts the demand for effective and affordable anti-obesity drugs.

• In November 2023, the FDA approved Zepbound developed by Eli Lilly and Company for chronic weight management in obese individuals or overweight individuals having at least one weight-related complication. The market is witnessing a surge in drug approvals by health agencies such as the United States Food and Drug Administration (FDA), which is expected to boost the North America anti-obesity drugs market share in the forecast period.

• In August 2023, Novo Nordisk A/S planned to acquire a Canada-based biotechnology company Inversago Pharma in a deal worth over USD 1 billion to expand its obesity and diabetes portfolio. Such strategic partnerships are expected to lead to accelerated development and commercial availability of innovative anti-obesity drugs.

North America Anti-Obesity Drugs Market Analysis

Anti-obesity drugs are expected to aid in weight management with minimal side effects by inducing fat absorption, appetite suppression, and metabolic enhancement, among others. In North America, there is a rising acceptance of obesity as a chronic disease requiring medical intervention rather than just lifestyle changes. This shift in perception coupled with heightened patient awareness and the presence of advanced healthcare infrastructure in the region is expected to contribute to the North America anti-obesity drugs market growth.

Recent data suggests that obesity rates in North America are sharply increasing. In the United States, 41.9% of adults are estimated to be obese, out of which, Black and Latino populations have the highest rates of obesity at 49.9% and 45.6%, respectively. The rising prevalence of obesity impacts the demand for effective and affordable anti-obesity therapeutics significantly. Furthermore, the increased focus on research in obesity management to combat the growing cases in the region is anticipated to boost market size in coming years.

One of the significant North America anti-obesity drugs market trends is the surge in drug approvals by health agencies such as the United States Food and Drug Administration (FDA). In November 2023, the FDA approved Eli Lilly and Company manufactured Zepbound (containing the active ingredient tirzepatide). It is designed for chronic weight management in obese individuals or overweight individuals having at least one weight-related complication. Zepbound is known to activate certain hormone receptors in the intestine that reduce food intake and suppress appetite. Its efficacy was evaluated in two randomized controlled trials which showed that Zepbound can result in a statistically significant reduction in body weight. The increased availability of such effective anti-obesity drugs is likely to elevate market value.

The market is witnessing increased merger and acquisition initiatives from the key market players. Such strategic partnerships are expected to lead to accelerated development and commercial availability of innovative therapeutics, thereby fuelling North America anti-obesity drugs market demand. In September 2023, Novo Nordisk A/S acquired a Canada-based biotechnology company, called Inversago Pharma in a deal worth over USD 1 billion. The partnership was intended to expand its obesity and diabetes portfolio. The company also aims to assess the potential of Inversago’s lead candidate, INV-202, which is known to block the CB1 receptor involved in the regulation of appetite and metabolism, in obesity and associated complications. Such substantial investments in the anti-obesity drug pipelines are expected to improve access to obesity treatments, which will positively impact the market share.

North America Anti-Obesity Drugs Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

North America Anti-Obesity Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Pfizer, Inc.

• Boehringer Ingelheim International GmbH

• GlaxoSmithKline PLC

• Novo Nordisk A/S

• Rhythm Pharmaceuticals, Inc.

• Gelesis Holdings Inc. (PureTech Health)

• Currax Pharmaceutical LLC (Currax Holdings USA LLC)

• Vivus LLC

• Cheplapharm Arzneimittel GmbH (Braun Beteiligungs GmbH)

• KVK Tech, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report